Compile Data Set for Download or QSAR
Report error Found 1071 with Last Name = 'werner' and Initial = 'm'
TargetMast/stem cell growth factor receptor Kit(Human)
Inhibikase Therapeutics

US Patent
LigandPNGBDBM612785(US11725005, Compound 119)
Affinity DataIC50: 4nMAssay Description:Kinase base buffer (50 mM HEPES, pH 7.5 0.0015% Brij-35; 10 mM MgCl22 mM DTT) and Stop buffer (100 mM HEPES, pH 7.5 0.015% Brij-35; 0.2% Coating Reag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2023
Entry Details
Go to US Patent

TargetMast/stem cell growth factor receptor Kit(Human)
Inhibikase Therapeutics

US Patent
LigandPNGBDBM481131(US10906896, Cpd 8300 | US10906896, Cpd 832 | US117...)
Affinity DataIC50: 4nMAssay Description:Kinase base buffer (50 mM HEPES, pH 7.5 0.0015% Brij-35; 10 mM MgCl22 mM DTT) and Stop buffer (100 mM HEPES, pH 7.5 0.015% Brij-35; 0.2% Coating Reag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2023
Entry Details
Go to US Patent

TargetMast/stem cell growth factor receptor Kit(Human)
Inhibikase Therapeutics

US Patent
LigandPNGBDBM481138(US10906896, Cpd 8200 | US11725005, Compound 8200)
Affinity DataIC50: 4.30nMAssay Description:Kinase base buffer (50 mM HEPES, pH 7.5 0.0015% Brij-35; 10 mM MgCl22 mM DTT) and Stop buffer (100 mM HEPES, pH 7.5 0.015% Brij-35; 0.2% Coating Reag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2023
Entry Details
Go to US Patent

TargetMast/stem cell growth factor receptor Kit(Human)
Inhibikase Therapeutics

US Patent
LigandPNGBDBM481143(US10906896, Cpd 8270 | US11725005, Compound 8270)
Affinity DataIC50: 4.90nMAssay Description:Kinase base buffer (50 mM HEPES, pH 7.5 0.0015% Brij-35; 10 mM MgCl22 mM DTT) and Stop buffer (100 mM HEPES, pH 7.5 0.015% Brij-35; 0.2% Coating Reag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2023
Entry Details
Go to US Patent

TargetMast/stem cell growth factor receptor Kit(Human)
Inhibikase Therapeutics

US Patent
LigandPNGBDBM612893(US11725005, Compound 8300)
Affinity DataIC50: 5.20nMAssay Description:Kinase base buffer (50 mM HEPES, pH 7.5 0.0015% Brij-35; 10 mM MgCl22 mM DTT) and Stop buffer (100 mM HEPES, pH 7.5 0.015% Brij-35; 0.2% Coating Reag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2023
Entry Details
Go to US Patent

TargetMast/stem cell growth factor receptor Kit(Human)
Inhibikase Therapeutics

US Patent
LigandPNGBDBM612783(US11725005, Compound 117)
Affinity DataIC50: 5.70nMAssay Description:Kinase base buffer (50 mM HEPES, pH 7.5 0.0015% Brij-35; 10 mM MgCl22 mM DTT) and Stop buffer (100 mM HEPES, pH 7.5 0.015% Brij-35; 0.2% Coating Reag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2023
Entry Details
Go to US Patent

TargetMast/stem cell growth factor receptor Kit(Human)
Inhibikase Therapeutics

US Patent
LigandPNGBDBM481145(US10906896, Cpd 8290 | US11725005, Compound 8290)
Affinity DataIC50: 5.70nMAssay Description:Kinase base buffer (50 mM HEPES, pH 7.5 0.0015% Brij-35; 10 mM MgCl22 mM DTT) and Stop buffer (100 mM HEPES, pH 7.5 0.015% Brij-35; 0.2% Coating Reag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2023
Entry Details
Go to US Patent

TargetMast/stem cell growth factor receptor Kit(Human)
Inhibikase Therapeutics

US Patent
LigandPNGBDBM612837(US11725005, Compound 404)
Affinity DataIC50: 5.80nMAssay Description:Kinase base buffer (50 mM HEPES, pH 7.5 0.0015% Brij-35; 10 mM MgCl22 mM DTT) and Stop buffer (100 mM HEPES, pH 7.5 0.015% Brij-35; 0.2% Coating Reag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2023
Entry Details
Go to US Patent

TargetMast/stem cell growth factor receptor Kit(Human)
Inhibikase Therapeutics

US Patent
LigandPNGBDBM612841(US11725005, Compound 405)
Affinity DataIC50: 5.90nMAssay Description:Kinase base buffer (50 mM HEPES, pH 7.5 0.0015% Brij-35; 10 mM MgCl22 mM DTT) and Stop buffer (100 mM HEPES, pH 7.5 0.015% Brij-35; 0.2% Coating Reag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2023
Entry Details
Go to US Patent

TargetTissue-type plasminogen activator(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM298092(US10118930, Example 302 | 3-[3-(2-tert-butoxyethyl...)
Affinity DataIC50: 6nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
Go to US Patent

TargetMast/stem cell growth factor receptor Kit(Human)
Inhibikase Therapeutics

US Patent
LigandPNGBDBM481130(US10906896, Cpd 830 | US11725005, Compound 830)
Affinity DataIC50: 6nMAssay Description:Kinase base buffer (50 mM HEPES, pH 7.5 0.0015% Brij-35; 10 mM MgCl22 mM DTT) and Stop buffer (100 mM HEPES, pH 7.5 0.015% Brij-35; 0.2% Coating Reag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2023
Entry Details
Go to US Patent

TargetMast/stem cell growth factor receptor Kit(Human)
Inhibikase Therapeutics

US Patent
LigandPNGBDBM481144(US10906896, Cpd 8280 | US11725005, Compound 8280)
Affinity DataIC50: 6.20nMAssay Description:Kinase base buffer (50 mM HEPES, pH 7.5 0.0015% Brij-35; 10 mM MgCl22 mM DTT) and Stop buffer (100 mM HEPES, pH 7.5 0.015% Brij-35; 0.2% Coating Reag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2023
Entry Details
Go to US Patent

TargetMast/stem cell growth factor receptor Kit(Human)
Inhibikase Therapeutics

US Patent
LigandPNGBDBM612740(US11725005, Compound 102)
Affinity DataIC50: 6.70nMAssay Description:Kinase base buffer (50 mM HEPES, pH 7.5 0.0015% Brij-35; 10 mM MgCl22 mM DTT) and Stop buffer (100 mM HEPES, pH 7.5 0.015% Brij-35; 0.2% Coating Reag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2023
Entry Details
Go to US Patent

TargetMast/stem cell growth factor receptor Kit(Human)
Inhibikase Therapeutics

US Patent
LigandPNGBDBM612739(US11725005, Compound 101)
Affinity DataIC50: 6.80nMAssay Description:Kinase base buffer (50 mM HEPES, pH 7.5 0.0015% Brij-35; 10 mM MgCl22 mM DTT) and Stop buffer (100 mM HEPES, pH 7.5 0.015% Brij-35; 0.2% Coating Reag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2023
Entry Details
Go to US Patent

TargetMast/stem cell growth factor receptor Kit(Human)
Inhibikase Therapeutics

US Patent
LigandPNGBDBM612764(US11725005, Compound 107)
Affinity DataIC50: 7.20nMAssay Description:Kinase base buffer (50 mM HEPES, pH 7.5 0.0015% Brij-35; 10 mM MgCl22 mM DTT) and Stop buffer (100 mM HEPES, pH 7.5 0.015% Brij-35; 0.2% Coating Reag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2023
Entry Details
Go to US Patent

TargetMast/stem cell growth factor receptor Kit(Human)
Inhibikase Therapeutics

US Patent
LigandPNGBDBM612767(US11725005, Compound 108)
Affinity DataIC50: 7.40nMAssay Description:Kinase base buffer (50 mM HEPES, pH 7.5 0.0015% Brij-35; 10 mM MgCl22 mM DTT) and Stop buffer (100 mM HEPES, pH 7.5 0.015% Brij-35; 0.2% Coating Reag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2023
Entry Details
Go to US Patent

TargetMast/stem cell growth factor receptor Kit(Human)
Inhibikase Therapeutics

US Patent
LigandPNGBDBM612772(US11725005, Compound 113)
Affinity DataIC50: 7.5nMAssay Description:Kinase base buffer (50 mM HEPES, pH 7.5 0.0015% Brij-35; 10 mM MgCl22 mM DTT) and Stop buffer (100 mM HEPES, pH 7.5 0.015% Brij-35; 0.2% Coating Reag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2023
Entry Details
Go to US Patent

TargetMast/stem cell growth factor receptor Kit(Human)
Inhibikase Therapeutics

US Patent
LigandPNGBDBM612741(US11725005, Compound 103)
Affinity DataIC50: 7.70nMAssay Description:Kinase base buffer (50 mM HEPES, pH 7.5 0.0015% Brij-35; 10 mM MgCl22 mM DTT) and Stop buffer (100 mM HEPES, pH 7.5 0.015% Brij-35; 0.2% Coating Reag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2023
Entry Details
Go to US Patent

TargetMast/stem cell growth factor receptor Kit(Human)
Inhibikase Therapeutics

US Patent
LigandPNGBDBM481128(US10906896, Cpd 809 | US11725005, Compound 809)
Affinity DataIC50: 7.80nMAssay Description:Kinase base buffer (50 mM HEPES, pH 7.5 0.0015% Brij-35; 10 mM MgCl22 mM DTT) and Stop buffer (100 mM HEPES, pH 7.5 0.015% Brij-35; 0.2% Coating Reag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2023
Entry Details
Go to US Patent

TargetTissue-type plasminogen activator(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM298254(US10118930, Example 452 | 3-(2-methylbutanoyl)-7-(...)
Affinity DataIC50: 8nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
Go to US Patent

TargetTissue-type plasminogen activator(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM298255(US10118930, Example 453 | 3-(cyclopropylcarbonyl)-...)
Affinity DataIC50: 8nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
Go to US Patent

TargetC-X-C chemokine receptor type 2(Human)
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM50203016(6-chloro-3-(3,4-dioxo-2-(phenylamino)cyclobut-1-en...)
Affinity DataIC50: 8nMAssay Description:Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/12/2012
Entry Details Article
PubMed
TargetC-X-C chemokine receptor type 2(Human)
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM50203030(3-[4-chloro-3-(4-ethyl-piperazine-1-sulfonyl)-2-hy...)
Affinity DataIC50: 8nMAssay Description:Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/12/2012
Entry Details Article
PubMed
TargetTissue-type plasminogen activator(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM298041(US10118930, Example 253 | 3-(2-methyl-1,3-thiazol-...)
Affinity DataIC50: 8.20nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
Go to US Patent

TargetMast/stem cell growth factor receptor Kit(Human)
Inhibikase Therapeutics

US Patent
LigandPNGBDBM612784(US11725005, Compound 118)
Affinity DataIC50: 8.40nMAssay Description:Kinase base buffer (50 mM HEPES, pH 7.5 0.0015% Brij-35; 10 mM MgCl22 mM DTT) and Stop buffer (100 mM HEPES, pH 7.5 0.015% Brij-35; 0.2% Coating Reag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2023
Entry Details
Go to US Patent

TargetTissue-type plasminogen activator(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM297950(US10118930, Example 166 | 7-(piperidin-4-yl)-3-{5-...)
Affinity DataIC50: 8.70nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
Go to US Patent

TargetMast/stem cell growth factor receptor Kit(Human)
Inhibikase Therapeutics

US Patent
LigandPNGBDBM612772(US11725005, Compound 113)
Affinity DataIC50: 8.90nMAssay Description:Kinase base buffer (50 mM HEPES, pH 7.5 0.0015% Brij-35; 10 mM MgCl22 mM DTT) and Stop buffer (100 mM HEPES, pH 7.5 0.015% Brij-35; 0.2% Coating Reag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2023
Entry Details
Go to US Patent

TargetTissue-type plasminogen activator(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM298115(US10118930, Example 327 | 7-(piperidin-4-yl)-3-(pi...)
Affinity DataIC50: 9nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
Go to US Patent

TargetTissue-type plasminogen activator(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM298123(US10118930, Example 335 | 3-(4-cyclohexyl-1,3-thia...)
Affinity DataIC50: 9nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
Go to US Patent

TargetMast/stem cell growth factor receptor Kit(Human)
Inhibikase Therapeutics

US Patent
LigandPNGBDBM612798(US11725005, Compound 305)
Affinity DataIC50: 9.20nMAssay Description:Kinase base buffer (50 mM HEPES, pH 7.5 0.0015% Brij-35; 10 mM MgCl22 mM DTT) and Stop buffer (100 mM HEPES, pH 7.5 0.015% Brij-35; 0.2% Coating Reag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2023
Entry Details
Go to US Patent

TargetTissue-type plasminogen activator(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM298009(US10118930, Example 224 | 3-[3-(4-fluorobenzyl)-1,...)
Affinity DataIC50: 9.70nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
Go to US Patent

TargetMast/stem cell growth factor receptor Kit(Human)
Inhibikase Therapeutics

US Patent
LigandPNGBDBM481137(US10906896, Cpd 8190 | US11725005, Compound 8190)
Affinity DataIC50: 9.70nMAssay Description:Kinase base buffer (50 mM HEPES, pH 7.5 0.0015% Brij-35; 10 mM MgCl22 mM DTT) and Stop buffer (100 mM HEPES, pH 7.5 0.015% Brij-35; 0.2% Coating Reag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2023
Entry Details
Go to US Patent

TargetPlasminogen [101-181](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290292(US10098883, Example 53 | 2-Oxo-4-(piperidin-4-yl)-...)
Affinity DataIC50: 10nMpH: 7.0Assay Description:The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/18/2019
Entry Details
Go to US Patent

TargetTissue-type plasminogen activator(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM298073(US10118930, Example 283 | 3-[5-(2-phenylethyl)-1,3...)
Affinity DataIC50: 10nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
Go to US Patent

TargetTissue-type plasminogen activator(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM298184(US10118930, Example 387 | Rel-3-{5-[(1R,2S)-2-meth...)
Affinity DataIC50: 10nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
Go to US Patent

TargetTissue-type plasminogen activator(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM298237(US10118930, Example 437 | 3-[3-(2-methoxyphenyl)-1...)
Affinity DataIC50: 10nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
Go to US Patent

TargetTissue-type plasminogen activator(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM298246(US10118930, Example 446 | 3-[3-(4-hydroxybenzyl)-1...)
Affinity DataIC50: 10nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
Go to US Patent

TargetPlasminogen [101-181](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290292(US10098883, Example 53 | 2-Oxo-4-(piperidin-4-yl)-...)
Affinity DataIC50: 10nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/15/2021
Entry Details
Go to US Patent

TargetMast/stem cell growth factor receptor Kit(Human)
Inhibikase Therapeutics

US Patent
LigandPNGBDBM481129(US10906896, Cpd 820 | US11725005, Compound 820)
Affinity DataIC50: 10nMAssay Description:Kinase base buffer (50 mM HEPES, pH 7.5 0.0015% Brij-35; 10 mM MgCl22 mM DTT) and Stop buffer (100 mM HEPES, pH 7.5 0.015% Brij-35; 0.2% Coating Reag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2023
Entry Details
Go to US Patent

TargetC-X-C chemokine receptor type 2(Human)
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM50203007(3-(2-bromophenylamino)-4-(4-chloro-2-hydroxy-3-(4-...)
Affinity DataIC50: 10nMAssay Description:Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/12/2012
Entry Details Article
PubMed
TargetPlasminogen [101-181](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290334(US10098883, Example 77 | 9-Fluoro-10-phenyl-4-(pip...)
Affinity DataIC50: 11nMpH: 7.0Assay Description:The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/18/2019
Entry Details
Go to US Patent

TargetPlasminogen [101-181](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290336(US10098883, Example 79 | 10-Chloro-8-methyl-4-(pip...)
Affinity DataIC50: 11nMpH: 7.0Assay Description:The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/18/2019
Entry Details
Go to US Patent

TargetTissue-type plasminogen activator(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM297791(US10118930, Example 16 | Ethyl 5-oxo-7-(piperidin-...)
Affinity DataIC50: 11nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
Go to US Patent

TargetTissue-type plasminogen activator(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM297845(US10118930, Example 68 | 5-[5-Oxo-7-(piperidin-4-y...)
Affinity DataIC50: 11nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
Go to US Patent

TargetTissue-type plasminogen activator(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM298063(US10118930, Example 274 | 3-[5-(3-chlorobenzyl)-1,...)
Affinity DataIC50: 11nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
Go to US Patent

TargetTissue-type plasminogen activator(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM298096(US10118930, Example 306 | 2-methyl-3-[3-(4-methylp...)
Affinity DataIC50: 11nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
Go to US Patent

TargetTissue-type plasminogen activator(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM298098(US10118930, Example 308 | 3-(4-ethyl-1,3-thiazol-2...)
Affinity DataIC50: 11nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
Go to US Patent

TargetTissue-type plasminogen activator(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM298127(US10118930, Example 338 | 3-(5-tert-butyl-1,3,4-ox...)
Affinity DataIC50: 11nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
Go to US Patent

TargetTissue-type plasminogen activator(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM298161(US10118930, Example 364 | Cyclobutyl 2-methyl-5-ox...)
Affinity DataIC50: 11nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
Go to US Patent

TargetTissue-type plasminogen activator(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM298170(US10118930, Example 373 | 7-(piperidin-4-yl)-3-(1,...)
Affinity DataIC50: 11nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
Go to US Patent

Displayed 1 to 50 (of 1071 total ) | Next | Last >>
Jump to: